Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 14;59(3):568.
doi: 10.3390/medicina59030568.

New Insights in the Setting of Transplant Oncology

Affiliations
Review

New Insights in the Setting of Transplant Oncology

Silvia Quaresima et al. Medicina (Kaunas). .

Abstract

Background and Objectives: Liver transplantation (LT) is the best strategy for curing several primary and secondary hepatic malignancies. In recent years, growing interest has been observed in the enlargement of the transplant oncology indications. This paper aims to review the most recent developments in the setting of LT oncology, with particular attention to LT for unresectable colorectal liver metastases (CRLM) and cholangiocellular carcinoma (CCA). Materials and Methods: A review of the recently published literature was conducted. Results: Growing evidence exists on the efficacy of LT in curing CRLM and peri-hilar and intrahepatic CCA in well-selected patients when integrating this strategy with (neo)-adjuvant chemotherapy, radiotherapy, or locoregional treatments. Conclusion: For unresectable CCA and CRLM management, several prospective protocols are forthcoming to elucidate LT's impact relative to alternative therapies. Advances in diagnosis, treatment protocols, and donor-to-recipient matching are needed to better define the oncological indications for transplantation. Prospective, multicenter trials studying these advances and their impact on outcomes are still required.

Keywords: colorectal liver metastases; intrahepatic cholangiocarcinoma; liver transplantation; neoadjuvant chemotherapy; peri-hilar cholangiocarcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Adam R., Karam V., Cailliez V., O Grady J.G., Darius Mirza D., Cherqui D., Klempnauer J., Salizzoni M., Pratschke J., Jamieson N., et al. 2018 Annual Report of the European Liver Transplant Registry (ELTR)—50-year evolution of liver transplantation. Transpl. Int. 2018;31:1293–1317. doi: 10.1111/tri.13358. - DOI - PubMed
    1. Lerut J., Foguenne M., Lai Q. Hepatocellular cancer selection systems and liver transplantation: From the tower of babel to an ideal comprehensive score. Updates Surg. 2021;73:1599–1614. doi: 10.1007/s13304-021-01078-4. - DOI - PMC - PubMed
    1. Mergental H., Porte R.J. Liver transplantation for unresectable hepatocellular carcinoma in patients without liver cirrhosis. Transpl. Int. 2010;23:662–667. doi: 10.1111/j.1432-2277.2010.01076.x. - DOI - PubMed
    1. Waisberg D.R., Pinheiro R.S., Nacif L.S., Rocha-Santos V., Martino R.B., Arantes R.M., Ducatti L., Lai Q., Andraus W., D’Albuquerque L.C. Resection for intrahepatic cholangiocellular cancer: New advances. Transl. Gastroenterol. Hepatol. 2018;3:60. doi: 10.21037/tgh.2018.08.03. - DOI - PMC - PubMed
    1. Line P.D., Dueland S. Liver transplantation for secondary liver tumours: The difficult balance between survival and recurrence. J. Hepatol. 2020;73:1557–1562. doi: 10.1016/j.jhep.2020.08.015. - DOI - PubMed